ArticleTissue engineering. Part A2022
Dual Delivery of BMP2 and IGF1 Through Injectable Hydrogel Promotes Cranial Bone Defect Healing.
Article in Tissue engineering. Part A, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Immune-epigenetic convergence in biomaterial-guided tissue regeneration.Materials today. Bio · 2026Article
- Hydrogel Implementing Drug Delivery in Cranial Bone Tissue Engineering.Journal of functional biomaterials · 2026Review
- Hydrogels for Bone Repair: Construction Strategies and Applications.Smart medicine · 2026Review
- Advancements in bone organoids: perspectives on construction methodologies and application strategies.Journal of advanced research · 2026Review
- A Bioinstructive Injectable Hydrogel for Enhancing Intrinsic Regeneration through Cell Recruitment and Training.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A smart nanocomposite bioactive ink for controlled siRNA delivery in calvarial mesenchymal stromal cells as a minimally invasive treatment for craniosynostosis.Regenerative biomaterials · 2026Article
- Cranial Bone Repair and Regeneration After Trauma: Forensic and Clinical Medico-Legal Consequences.Bioengineering (Basel, Switzerland) · 2025Review
- Molecular Engineering of Recombinant Protein Hydrogels: Programmable Design and Biomedical Applications.Gels (Basel, Switzerland) · 2025Review
- Effects of Insulin-like Growth Factor 1 on the Maintenance of Cell Viability and Osteogenic Differentiation of Gingiva-Derived Mesenchymal Stem Cell Spheroids.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- The use of hydrogel microspheres as cell and drug delivery carriers for bone, cartilage, and soft tissue regeneration.Biomaterials translational · 2024Review
- Biomimetic Inspired Hydrogels for Regenerative Vertebral Body Stenting.Current osteoporosis reports · 2023Review
- Targeting RORα in macrophages to boost diabetic bone regeneration.Cell proliferation · 2023Article
- Enhanced Bone Formation by Rapidly Formed Bony Wall over the Bone Defect Using Dual Growth Factors.Tissue engineering and regenerative medicine · 2023Article
- An osteoinductive and biodegradable intramedullary implant accelerates bone healing and mitigates complications of bone transport in male rats.Nature communications · 2023Article
- Biomedical Applications of Collagen.Bioengineering (Basel, Switzerland) · 2023Article
- Drug delivery systems based on polyethylene glycol hydrogels for enhanced bone regeneration.Frontiers in bioengineering and biotechnology · 2023Review
- Functional Hydrogels and Their Applications in Craniomaxillofacial Bone Regeneration.Pharmaceutics · 2022Review
- Matrix-bound Cyr61/CCN1 is required to retain the properties of the bone marrow mesenchymal stem cell niche but is depleted with aging.Matrix biology : journal of the International Society for Matrix Biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Critical-sized cranial bone defect remains a great clinical challenge. With advantages in regenerative medicine, injectable hydrogels incorporated with bioactive molecules show great potential in promoting cranial bone repair. Recently, we developed a dual delivery system by sequential release of bone morphogenetic protein 2 (BMP2) followed by insulin-like growth factor 1 (IGF1) in microparticles (MPs), and an injectable alginate/collagen (alg/col)-based hydrogel. In this study, we aim to evaluate the effect of dual delivery of BMP2 and IGF1 in MPs through the injectable hydrogel in critical-sized cranial bone defect healing. The gelatin MPs loaded with BMP2 and poly(lactic-co-glycolic acid)-poly(ethylene glycol)-carboxyl (PLGA-PEG-COOH) MPs loaded with IGF1 were prepared, respectively. The encapsulation efficiency and release profile of growth factors in MPs were measured. A cranial defect model was applied to evaluate the efficacy of the dual delivery system in bone regeneration. Adult Sprague Dawley rats were subjected to osteotomy to make an ⌀8-mm cranial defect. The injectable hydrogel containing MPs loaded with BMP2 (2 μg), IGF1 (2 μg), or a combination of BMP2 (1 μg) and IGF1 (1 μg) were injected to the defect site. New bone formation was evaluated by microcomputed tomography, histological analysis, and immunohistochemistry after 4 or 8 weeks. Data showed that dual delivery of the low-dose BMP2 and IGF1 in MPs through alg/col-based hydrogel successfully restored cranial bone as early as 4 weeks after implantation, whose effect was comparable to the single delivery of high-dose BMP2 in MPs. In conclusion, this study suggests that dual delivery of BMP2 and IGF1 in MPs in alg/col-based hydrogel achieves early bone regeneration in critical-sized bone defect, with advantage in reducing the dose of BMP2. Impact Statement Sequential release of bone morphogenetic protein 2 (BMP2) followed by insulin-like growth factor 1 (IGF1) in two different microparticles promotes critical-sized bone defect healing. This dual delivery system reduces the dose of BMP2 by supplementing IGF1, which may diminish the potential side effects of BMP2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.